B
Bull
Bull · 25%AEON
$1.02
Precio del escenario
$0.255
-0.015 (-6.01%)Al cierre
Loading chart…
- High
- 0.279
- Open
- 0.279
- VWAP
- 0.26
- Vol
- 374.21K
- Mkt Cap
- 41.47M
- Low
- 0.250
- Amount
- 97.69K
- EV/EBITDA, TTM
- 0.00
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
AI analysis of Aeon Biopharma Inc (AEON)
buyAeon Biopharma Inc is a good buy right now due to its recent compliance restoration with NYSE requirements and a successful public offering that raised approximately $13.6 million, significantly boosting investor confidence. The current price is $0.31, and the RSI is at 79.458, indicating strong momentum. However, the main risk is the company's high net losses, with a reported net income of -11,793,000 USD in Q1 2026, which could affect future performance.
Métricas de valoración
The current forward P/E ratio for Aeon Biopharma Inc (AEON) is 1.16, compared to its 5-year average forward P/E of -0.53.
Alphio AI Price Scenarios for AEON
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-24NewsfilterAEON Appoints New Chief Regulatory Officer to Advance Biosimilar Development
8.508-03seekingalphaAEON Biopharma Regains NYSE Compliance
8.507-14NASDAQ.COMAEON Biopharma Announces Upsized Public Offering Expected to Raise $13.75 Million
- 8.507-14seekingalpha
AEON Biopharma Prices Public Offering to Raise $43.3M
- 9.505-15seekingalpha
AEON Biopharma Reports Q1 Financial Results
AEON FAQ — answered by Alphio AI
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Aeon Biopharma Inc is a good buy right now due to its recent compliance restoration with NYSE requirements and a successful public offering that raised approximately $13.6 million, significantly boosting investor confidence. The current price is $0.31, and the RSI is at 79.458, indicating strong momentum. However, the main risk is the company's high net losses, with a reported net income of -11,793,000 USD in Q1 2026, which could affect future performance.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.